Actinium Pharmaceuticals (ATNM) 15th Annual LD Micro Invitational 2025 summary

Strategic and clinical program updates

• Revitalized clinical programs and a new strategy are set to deliver multiple clinical, regulatory, and strategic milestones in 2025.

• Lead program Actimab-A is advancing in partnership with the NCI, with new trials in frontline AML and solid tumors, including a pivotal phase II/III trial.

• Iomab-ACT is being developed to improve access and outcomes for myeloid therapies, with two clinical trials active in 2025 and data expected in the second half of the year.

Research and development investments

• Enhanced R&D infrastructure has generated preclinical data supporting clinical programs and pipeline advancement.

• Two abstracts have been accepted for presentation at the AACR conference.

• Plans are underway to build an in-house radiotherapy manufacturing facility starting this year.

• Ended 2024 with $72.9 million in cash, expected to fund operations into mid-2027.

Clinical trial progress and market opportunities

• Actimab-A is being added to venetoclax plus HMA therapy in newly diagnosed AML patients, with initial data expected by year-end.

• Expanding Actimab-A into solid tumors in combination with Keytruda and Opdivo, targeting CD33-expressing MDSCs to potentially resensitize tumors to PD-1 inhibitors.